Transposon Therapeutics, Inc.
Clinical trials sponsored by Transposon Therapeutics, Inc., explained in plain language.
-
New drug TPN-101 tested for rare brain disorder PSP
Disease control CompletedThis study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the …
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New drug shows promise for rare genetic brain diseases
Disease control CompletedThis study tested a new medicine called TPN-101 in 42 people who have ALS or frontotemporal dementia caused by a specific gene change (C9orf72). The main goal was to see if the drug is safe and tolerable. Researchers also looked at how the drug moves in the body and whether it af…
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC